GRAIL, LLC experienced a significant boost in its stock price following positive news regarding its cancer detection test.
GRAIL, LLC (NASDAQ:GRAL) saw its stock price surge by 15.38% yesterday, closing at CA$125.21. This rally was driven by a favorable endorsement from a US FDA advisory panel for its multi-cancer early detection blood test, Galleri.
Advertisement
GRAIL, LLC
GRAL.US
GRAL.US
GRAIL, LLC
WealthAwesomeMarket cap
$5.59B
52W high
$126.81
52W low
$41.50
1W change
+56.61%
Beta
3.25
Analyst Price Targets
Based on 4 analysts covering GRAL · as of Sep 25, 2026
Wall Street analysts forecast GRAL stock price to fall 31.4% over the next 12 months.
Consensus
Buy3.50 / 5.00
Avg. Target
C$85.90
-31.4% Upside
Previously C$82.40 on Sep 23, 2026
Current Price
C$125.21
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GRAL's historical volatility
30-Day Vol
100.0%
Annualized
90-Day Vol
89.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$149.69
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$132.89 | C$94.11 – C$187.64 |
| 60 trading days | C$141.04 | C$86.58 – C$229.75 |
| 90 trading days | C$149.69 | C$82.35 – C$272.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The FDA panel's endorsement could pave the way for broader insurance coverage of Galleri, potentially increasing GRAIL's market reach and revenue.
GRAIL's stock surged by 15.38% yesterday
The surge reflects growing investor confidence in GRAIL's future prospects following the FDA endorsement.
Bull case
The positive vote from the FDA panel shows strong support for Galleri. This suggests the test could become a valuable tool for early cancer detection, which may lead to increased sales and market share.
Bear case
Despite the good news, the test's reliance on additional screening methods might limit its immediate market impact. The company also faces risks associated with false positives and negatives.
Advertisement
FDA Panel's Endorsement
The FDA advisory panel voted 6-4 in favor of the Galleri test, indicating reasonable evidence of its effectiveness in early cancer detection. Additionally, a unanimous 10-0 vote confirmed the test's safety, while a 7-2 vote suggested that the benefits outweigh the risks. This endorsement is a crucial step towards potential Medicare and private insurance coverage.
Market Implications
With the FDA panel's backing, GRAIL could see an increase in demand for the Galleri test. If approved, the test could not only enhance early cancer detection rates but also significantly expand GRAIL's market presence. Investors are optimistic about the future revenue streams that could arise from wider insurance coverage.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
